EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Effectiveness and Safety After a Switch to Tildrakizumab: A Real World Multicenter Italian Study in Psoriasis

Eugenia Veronica Di Brizzi, Dario Buononato, Pierfrancesco Benvenuto, Giuseppe Argenziano, Rocco De Pasquale, Carmen Silvia Fiorella, Claudia Giofrè, Maria Letizia Musumeci, Giovanni Palazzo, Leonardo Zichichi, Anna Balato

Dermatology Practical & Conceptual · 31.10.2023 · e2023215

DOI: 10.5826/dpc.1304a215 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Dermatology Practical & Conceptual, online erschienen am 31.10.2023. Verfasst von Eugenia Veronica Di Brizzi und 10 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology Unit, University of Campania "Luigi Vanvitelli", Naples, Italy. Die Arbeit wurde bisher 15-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Tildrakizumab is a humanized IgG1κ monoclonal antibody targeting the p19 subunit of interleukin (IL)-23, approved in 2018 for the treatment of patients with moderate-to-severe chronic plaque psoriasis.

Objectives

This study aimed to evaluate the effectiveness, safety and survival of tildrakizumab in the medium term (48 weeks) in psoriatic patients failure to previous biologic treatment in a real world setting.

Methods

This was a retrospective, multicenter observational study that included adult patients with moderate-to-severe plaque psoriasis, failure to previous biologic therapy, consecutively treated with tildrakizumab. PASI and BSA values were recorded at baseline, at 12 and 48 weeks of treatment. Safety and tolerability of tildrakizumab were investigated by examining the presence of any adverse events.

Results

Overall 51 patients were enrolled. Baseline disease severity was moderate to severe with a mean PASI score of 19.2 ± 8.5, mean BSA of 16 ± 10.4, and mean DLQI of 18.2 ± 6.8. A significant reduction in the mean PASI score was detected at 12 weeks of tildrakizumab therapy (3.5 ± 2.7, p < 0.001), with a further improvement at week 48 (0.6 ± 1.5, p < 0.001). At week 12, there was a great improvement in BSA score for all groups (p

Autor:innen und Institutionen

  • Dermatology Unit, University of Campania "Luigi Vanvitelli", Naples, Italy.
  • U.O.C. Dermatology Unit, "G. Rodolico-S. Marco" Hospital, Catania, Italy.
  • Dermatology Unit, "Monsignor Raffaele Dimiccoli" Hospital, Barletta, Italy.
  • U.O.C. Dermatology Unit, "Papardo" Hospital, Messina, Italy.
  • Dermatology Unit, Hospital of Tinchi Pisticci, Italy.
  • U.O.C. Dermatology Unit, "S. Antonio Abate" Hospital, Trapani, Italy.

Zitieren

APA

Di Brizzi, E. V., Buononato, D., Benvenuto, P., Argenziano, G., De Pasquale, R., Fiorella, C. S., Giofrè, C., Musumeci, M. L., Palazzo, G., Zichichi, L., & Balato, A. (2023). Effectiveness and Safety After a Switch to Tildrakizumab: A Real World Multicenter Italian Study in Psoriasis. Dermatology Practical & Conceptual, e2023215. https://doi.org/10.5826/dpc.1304a215

Vancouver

Di Brizzi EV, Buononato D, Benvenuto P, Argenziano G, De Pasquale R, Fiorella CS, et al. Effectiveness and Safety After a Switch to Tildrakizumab: A Real World Multicenter Italian Study in Psoriasis. Dermatology Practical & Conceptual. 2023:e2023215. doi:10.5826/dpc.1304a215

BibTeX
@article{DiBrizzi2023,
  author = {Di Brizzi, Eugenia Veronica and Buononato, Dario and Benvenuto, Pierfrancesco and Argenziano, Giuseppe and De Pasquale, Rocco and Fiorella, Carmen Silvia and Giofrè, Claudia and Musumeci, Maria Letizia and Palazzo, Giovanni and Zichichi, Leonardo and Balato, Anna},
  title = {Effectiveness and Safety After a Switch to Tildrakizumab: A Real World Multicenter Italian Study in Psoriasis},
  journal = {Dermatology Practical & Conceptual},
  year = {2023},
  pages = {e2023215},
  doi = {10.5826/dpc.1304a215}
}
Kostenlos starten →